Jellinek
2 papers in the library · publishing 2025
The Journal of Clinical Psychiatry October 13, 2025 Pim B. van der Meer, Sebastiaan O Verboeket, Arjen J. C. Slooter et al.
NMDA receptor antagonists like ketamine may help treat catatonia. This systematic review evaluated the efficacy and safety of ketamine and esketamine for catatonia, finding that the available evidence suggests these drugs could be beneficial, but the data are limited and further research is needed to confirm their role.
Psychedelic Medicine October 8, 2025 Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.
A systematic review of clinical trials found limited evidence that psychoactive tryptamines other than psilocybin and ibogaine are effective for treating substance use disorders. Four trials involving 176 patients with alcohol use disorder tested dipropyltryptamine and diethyltryptamine. Abstinence rates ranged from 10% to 38% at 26 weeks of follow-up, and severity of alcohol use did not differ between the tryptamine and control groups. Adverse effects were poorly reported. The review concludes that studies are scarce and show limited evidence for effectiveness in treating addictive disorders.